Lloyd E. Johnson Joins Haemonetics' Board of Directors; Ellen Zane Announced as New Board Chair
08/09/2021 - 06:45 AM
BOSTON , Aug. 9, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced the election of Lloyd E. Johnson to its Board of Directors. In addition, the company announced that Ellen Zane will serve as the new independent Chair of Haemonetics' Board of Directors.
Johnson served as Global Managing Director, Finance and Internal Audit at Accenture Corporation from 2004 until his retirement in 2015, where he led the global management consulting company's audit organization and provided strategic leadership in finance, risk, compliance and governance. Prior to joining Accenture, Johnson served as Executive Director, M&A and General Auditor for Delphi Automotive PLC, a global automotive technology industry leader. He has also held senior financial leadership positions at Emerson Electric Corporation, Sara Lee Corporation and Shaw Food Services. Johnson currently serves on the boards of Apogee Enterprises, Inc.; Beazer Homes USA , Inc.; AARP, where he is second Vice Chair; and the NACD Carolinas Chapter.
"With over 35 years of senior finance leadership experience, Lloyd brings significant expertise and strategic insight to the Board in the areas of accounting and financial management, mergers and acquisitions, international operations, business development, corporate governance and enterprise risk management," said Ellen Zane , Chair of Haemonetics' Board of Directors. "We look forward to welcoming him to our Board of Directors as Haemonetics pursues its strategies to deliver shareholder value."
Johnson earned his bachelor's and master's degrees from the University of South Carolina and a Master of Business Administration from Duke University . He was named one of the "Most Influential Black Corporate Directors" by Savoy in 2017 and has been listed as a "Director to Watch" in 2018 and 2020 by Directors & Boards .
Zane succeeds Richard Meelia , who retired as Board Chairman and a director effective as of Haemonetics' 2021 Annual Meeting of Shareholders on August 6, 2021 . "Ellen is a nationally renowned healthcare leader and has been an invaluable member of the Haemonetics Board, including her service as Chair of the Governance and Compliance Committee," said Mr. Meelia. "She has my full support and confidence as the new Chair of the Board of Directors." Zane rejoined Haemonetics' Board of Directors in 2018 after previously serving on the company's Board from 2012-2016.
About Haemonetics Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com .
https://www.prnewswire.com/news-releases/lloyd-e-johnson-joins-haemonetics-board-of-directors-ellen-zane-announced-as-new-board-chair-301350979.html
SOURCE Haemonetics Corporation
HAE Rankings
#2026 Ranked by Stock Gains
HAE Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Boston
About HAE
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
